Company intelligence / Profile preview

Retrace Group

Ownership: Private
Development stage: Commercial

Overview

Retrace Group, through its subsidiary Retrace AV Limited, has developed and launched an innovative paint product that destroys SARS-CoV-2—the virus responsible for COVID-19—within 30 minutes of contact. The company leads an international team of manufacturers and distributors to deliver this antimicrobial solution for infection control in various environments.

Therapeutic areas: Infectious Diseases
Modalities: Non-pharmacological therapy
Industry: Non-Drug Biotech

Drug pipeline

1 asset

Retrace AV

Commercial

Indications: COVID-19, Antimicrobial protection

Beyond the preview

Go deeper on Retrace Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retrace Group.

Explore the full profile